Skip to content


Illumina Announces Novel Human Exome Content Available on Multiple BeadChip Formats

Provides Over 250,000 Functional Variants to Uncover Biologically Significant Associations

MONTREAL, Oct 12, 2011 (BUSINESS WIRE) -- Illumina, Inc. (NASDAQ: ILMN) today announced the availability of novel human exome content for three new microarrays, the Infinium HumanExome, OmniExpressExome, and HumanOmni5Exome BeadChips. This content provides rapid and economical interrogation of over 250,000 variants within the protein coding regions of the human genome, enabling a range of study types aimed at uncovering functionally relevant disease associations.

The BeadChip content was selected by prominent geneticists with the goal of delivering the most extensive catalog of exome variants. Selected markers were identified from over 12,000 sequenced genomes representing diverse populations and a number of common conditions, including type 2 diabetes, cancer, and metabolic and psychiatric disorders.

"These arrays were created through a close collaboration with leading experts on human disease-related variation," said Tristan Orpin, Illumina's Senior Vice-President and Chief Commercial Officer. "The success of this effort illustrates the power of using Illumina's flexible array technology to incorporate new variants discovered from recent studies. Researchers can use these BeadChips to obtain new insights for previously genotyped cohorts, or optimize GWAS projects by maximizing coverage of coding variants within genes."

The use of both array and next-generation sequencing to develop these BeadChips underscores the complementary roles of these technologies. Novel variants discovered through the power of next-generation sequencing have been deployed on Illumina BeadChips so that researchers can rapidly process large sample numbers to achieve greater statistical power in a cost-effective, straight-forward manner.

"Prior to the consolidation of this exome content, we did not have a fast and economical array to survey almost all of the variation in the coding regions of the human genome," said Benjamin Neale, Assistant in Medicine at Massachusetts General Hospital. "We can now study very rare coding variants in dramatically larger sample numbers than would be currently practical for sequencing."

Researchers can also add additional custom markers on all three BeadChips to target specific regions of the genome with higher density, focus on populations of interest, or incorporate selected disease-related variants.

For more information, please visit

About Illumina

Illumina ( is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release contains forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

SOURCE: Illumina, Inc.

Illumina, Inc.
Kevin Williams, MD
Investor Relations
Laura Trotter
Public Relations

Recent Articles

The Power and Promise of Liquid Biopsies
The Power and Promise of Liquid Biopsies
New Liquid Biopsy and High-Throughput Assays Join TruSight Oncology Portfolio
New Liquid Biopsy and High-Throughput Assays Join TruSight Oncology Portfolio
Texas A&M Deploys DRAGEN
Texas A&M Deploys DRAGEN